![In shock move, EU panel rejects Alzheimer's drug Leqembi](/sites/default/files/styles/x_large/public/2024-07/Leqembi%20denied.jpg?itok=2ryL2n2P)
In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
![Third Arc's $165m for T cell engagers, plus other bio rounds](https://pharmaphorum.com/sites/default/files/styles/x_large/public/2023-09/micheile-henderson-green-shoots-unsplash.jpg?itok=QBkWgDFy)
Third Arc's $165m for T cell engagers, plus other bio rounds
This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also
![Map showing the East West Rail route that lies at the heart of the Oxford-Cambridge supercluster plan](/sites/default/files/styles/x_large/public/2024-07/east-west-rail-route-final.jpg?itok=sbvdZ_oO)
AZ joins call for new UK PM to back Oxford-Cambridge hub
In a letter to the new UK Prime Minister Keir Starmer, leading figures in industry and academia have called for a plan to turn the Oxford-Cambridge region into the 'crown jewel' of the nati
![Pfizer's haemophilia B gene therapy gets EU green light](https://pharmaphorum.com/sites/default/files/styles/x_large/public/2023-07/Pfizer.jpg?itok=e4NKUkaB)
Pfizer's haemophilia B gene therapy gets EU green light
There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand
![Shingles shot could be a simple way to delay dementia](https://pharmaphorum.com/sites/default/files/styles/x_large/public/2023-03/constant-gdc48d2402_640_0.jpg?itok=Mfog46ip)
Shingles shot could be a simple way to delay dementia
Vaccination with GSK's recombinant shingles vaccine, Shingrix, could delay the onset of dementia, according to researchers in the UK.
Partner Content
![Credit: Novo Nordisk](/sites/default/files/styles/x_large/public/2024-07/Novo-Nordisk.jpg?itok=gDDBn0MU)
Novo Nordisk seeks to target heart disease with Cardior acqu...
Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their
![6th Inflammasome Therapeutics Summit banner](/sites/default/files/styles/x_large/public/2024-07/6th_Inflammasome-Therapeutics.jpg?itok=sx2xvXmX)
6th Inflammasome Therapeutics Summit
In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
![2nd Covalent Drug Discovery & Development Summit banner image](/sites/default/files/styles/x_large/public/2024-07/2nd-Covalent-Drug-Discovery.jpg?itok=MVFElDnd)
2nd Covalent Drug Discovery & Development Summit
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & B
![7th TPD & Induced Proximity Summit banner image](/sites/default/files/styles/x_large/public/2024-07/7th-TPD-%26-Induced-Proximity-Summit-banner.jpg?itok=l6NbtAWC)
7th TPD & Induced Proximity Summit
Fast-Track Discovery, Development & Approval of Selective, Safe & Clinically Relevant TACs & Glues for Degradation, Stabilization, & Phosphorylation to Successfully Address
![5th Gene Therapy Immunogenicity Summit banner](/sites/default/files/styles/x_large/public/2024-07/Gene-Therapy-Immunogenicity-Summit.jpg?itok=7KYW23p8)
5th Gene Therapy Immunogenicity Summit
Optimise Safety & De-Risk Efficacy of Viral Vector Based Gene Therapies